服务热线
15339069646服务热线
15339069646| Item | Name | Cat. No. | Tag/Conjugates |
| Anti-TSLP;ALB mAbs [Lunsekimig2 Biosimilar] (MABL-4908) | MABL-4908 | ELISA, FACS, Functional assay, in vivo binding | na;na, na;na |
| Anti-TSLP mAbs [Lunsekimig3 Biosimilar] (MABL-4909) | MABL-4909 | ELISA, FACS, Functional assay, in vivo binding | na, na |
| Anti-LYPD3 mAbs [Lupartumab Biosimilar] (MABL-4910) | MABL-4910 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-PDCD1/CD279/PD1 mAbs [Lipustobart Biosimilar] (MABL-4879) | MABL-4879 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-SIGLEC8/SAF2 mAbs [Lirentelimab Biosimilar] (MABL-4880) | MABL-4880 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-KIRD2 mAbs [Lirilumab Biosimilar] (MABL-4881) | MABL-4881 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CLEC4C mAbs [Litifilimab Biosimilar] (MABL-4882) | MABL-4882 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-LRRC32 mAbs [Livmoniplimab Biosimilar] (MABL-4883) | MABL-4883 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CLDN1 mAbs [Lixudebart Biosimilar] (MABL-4884) | MABL-4884 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDL1/CD274 mAbs [Lodapolimab Biosimilar] (MABL-4885) | MABL-4885 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-PCSK9 mAbs [Lodelcizumab Biosimilar] (MABL-4886) | MABL-4886 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-F11;F11 mAbs [Lofacimig Biosimilar] (MABL-4887) | MABL-4887 | ELISA, FACS, Functional assay, in vivo binding | G1, na |
| Anti-IL31 mAbs [Lokivetmab Biosimilar] (MABL-4888) | MABL-4888 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-SARS-CoV-2 Spike RBD mAbs [Lomtegovimab Biosimilar] (MABL-4889) | MABL-4889 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDCD1/CD279/PD1;HAVCR2/TIM3 mAbs [Lomvastomig Biosimilar] (MABL-4890) | MABL-4890 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-CD19 mAbs [Loncastuximab Biosimilar] (MABL-4891) | MABL-4891 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IGF1R/CD221 mAbs [Lonigutamab Biosimilar] (MABL-4892) | MABL-4892 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-PDCD1/CD279/PD1;CTLA4/CD152 mAbs [Lorigerlimab Biosimilar] (MABL-4893) | MABL-4893 | ELISA, FACS, Functional assay, in vivo binding | G4;G4, Kappa;Kappa |
| Anti-Influenza B Virus mAbs [Lesofavumab Biosimilar] (MABL-4863) | MABL-4863 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IAP/CD47 mAbs [Letaplimab Biosimilar] (MABL-4864) | MABL-4864 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
联系我们
Copyright © 2012-2029 西安迈博睿（Mabioway）生物科技有限公司 版权所有
地址：陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话：15339069646 邮箱：info@mabioway.cn